About
Immunotherapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
5
As Collaborator
4
Total Enrollment
151
By Phase
EARLY_PHASE1: 2PHASE2: 1PHASE3: 1PHASE1/PHASE2: 2PHASE1: 1NA: 2
By Status
ACTIVE_NOT_RECRUITING: 5RECRUITING: 2NOT_YET_RECRUITING: 1UNKNOWN: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07063030Collaborator
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
EARLY_PHASE1Not yet recruiting
13 participants
Started: Jul 15, 2025 · Completed: Dec 31, 2030
NCT07053358Collaborator
Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
EARLY_PHASE1Recruiting
10 participants
Started: Jul 2, 2025 · Completed: Dec 30, 2029
NCT06196840Lead Sponsor
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
PHASE2Active, not recruiting
50 participants
Started: Jan 24, 2024 · Completed: Oct 31, 2029
NCT07054632Lead Sponsor
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
PHASE3Active, not recruiting
30 participants
Started: Sep 13, 2023 · Completed: Aug 31, 2029
NCT06212297Lead Sponsor
Fellow-eye Study (FE) of LX101 in Subjects With Inherited Retinal Dystrophy
PHASE1/PHASE2Active, not recruiting
9 participants
Started: Sep 12, 2023 · Completed: Mar 31, 2029
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...